HER-2 Positive Breast Cancer Recruiting Phase 3 Trials for Capecitabine (DB01101)

IndicationStatusPhase
DBCOND0042425 (HER-2 Positive Breast Cancer)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02492711Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerTreatment